Publications

Journal Publications


  • Wei W, Knapp K, Wang L, Chen CI, Craig GL, Ferguson K, Schwartzman S. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. Adv Ther. 2017 Aug;34(8):1936-1952. Article PDF

 

Conference Abstracts


  • Alemao, E., Knapp, K., Anupindi, V., Annamalai, S. Craig, G. (2017). Treatment effects of abatacept and anti-tnf in patients with ra with poor prognostic factors: data from community rheumatology clinics  Article
  • Craig, G., Knapp, K., Ferguson, K., Schwartzman, S. (2016). The “Financial Toxicity” of Therapy in Patients with Rheumatoid Arthritis.  Arthritis & Rheumatism,68(S10 Suppl). Article
  • Schwartzman, S., Knapp, K., Craig, G. (2016). The Importance of Outcome Measures in Ankylosing Spondylitis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Cohort. Arthritis & Rheumatism, 68(S10 Suppl). Article
  • Craig, G., Knapp, K., Ferguson, K., Tavares, R., Bell, M., Schwartzman, S. (2016). Evaluation of a Pre-Assessment Tool to Define the Spectrum of Autoimmune Diseases in an Underserved Environment. Arthritis & Rheumatism, 68(S10 Suppl). Article
  • Schwartzman, S., Knapp, K., Craig, G., Ferguson, K., (2016). The Importance of Outcome Measures in Rheumatoid Arthritis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Setting. Arthritis & Rheumatism,68(S10 Suppl). Article
  • Wei, W., Knapp, K., Wang, L., Chen, C., Craig, G., Ferguson, K., & Schwartzman, S. (2015). Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis. Arthritis & Rheumatism, 67(S10 Suppl), 3346. Article
  • Schwartzman, S., Knapp, K., Craig, G., Ferguson, K., & Kenney, H. (2015). Use of Tofacitinib in a Real World Setting:  Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial. Arthritis & Rheumatism, 67(S10 Suppl), 652-653. Article
  • Schwartzman, S., Knapp, K., Craig, G., Ferguson, K., & Kenney, H. (2015). Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting. Arthritis & Rheumatism, 67(S10 Suppl), 3153. Article
  • Schwartzman, S., Knapp, K., Craig, G., Ferguson, K., & Kenney, H. (2015). Efficacy of Tofacitinib in a Real World Setting Using the Database Jointman. Arthritis & Rheumatism, 67(S10), 653-654. Article
  • Schwartzman, S., Knapp, K., Craig, G., Ferguson, K., & Kenney, H. (2014). United States Rheumatologists Who Consistently measure Disease Activity In Rheumatoid Arthritis Patients (RA) Are Achieving Low Disease Activity (LDA) and Remission (R). Ann Rheum Dis, 73(Suppl2), AB0290. Article
  • Craig, G., Kenney, H., Knapp, K., & Schwartzman, S. (2013). Rheumatologists Who Are Consistently Using An Objective Outcome Instrument Do Not “Treat To Target” In a Real World Setting. Arthritis & Rheumatism, 64(Suppl2) 2300. Article